The FDA record for K261677 lists Aramis Global AI Consultancies, LLC as applicant, with a Dubai address and a correspondence address through a Connecticut-based consultant. The device is Artificial Intelligence Renal Assessment (AIRA) Version 1, reviewed under regulation 21 CFR 892.2050 as a medical image management and processing system, Class II, product code QIH, advisory committee Radiology. The decision was Substantially Equivalent, clearance type Traditional, with a Summary statement. The stated indications cover non-invasive processing of CT kidney images using automatic image segmentation and measurement of anatomical structures with artificial intelligence and machine-learning algorithms. [1][3]

The K261677 submission and its scope

The filing carries a date received of May 21, 2026, and a decision date of September 15, 2026. The FDA clearance letter is dated September 15, 2026 and references device documentation dated August 15, 2026, received August 17. The letter identifies the regulation as 21 CFR 892.2050, regulatory class Class II, product code QIH, and states the subject device matches its predicate on regulation, description, classification and product code. [1][3]

The indications for use in the clearance letter are limited to non-invasive processing of CT kidney images, using automatic image segmentation and measurement of anatomical structures through artificial intelligence and machine-learning algorithms. The record does not describe clinical performance results, training data or deployment arrangements. [3]

AIRA within the published Aramis product line

Aramis Imaging LLP's published product pages place AIRA among Solutions & AI offerings alongside ReVue, Protos, quantSynth and diyAI. The Protos page describes AIRA as AI-assisted renal assessment with automated segmentation and analysis of the kidneys on CT, and states it is FDA 510(k) cleared. The same page lists quantSynth for synthetic and parametric MRI and SUVue for AI-assisted PET-CT SUV assessment. [6][7]

The manufacturer's pages state that FDA 510(k) clearance K261677 applies to AIRA only, for the indications stated on the AIRA page. The same notices describe the software as intended for trained healthcare professionals, with AI features assisting the radiologist and every report reviewed and signed by a qualified doctor. [4][6][7]

Platform context and the applicant question

Aramis Imaging LLP documentation describes Radium as a zero-footprint radiology platform covering registration, scheduling, reading, reporting, delivery and billing in a browser, with Radium Pro as a superset for institutions. A products page lists Radium components including RIS, PACS, billing, analytics and compliance, plus HealthCard as a laboratory information system integrated with Radium and Spin for services and API orchestration. [4][6]

The FDA applicant name, Aramis Global AI Consultancies, LLC, differs from the Aramis Imaging LLP name used across the published website and brochures. The numbered sources do not state a corporate relationship, parent entity or brand ownership between the two names, so any such link remains unverified. The Dubai address in the FDA record is a filing address and is not established as a headquarters. [1][4][5]

What the record does not establish

The linked collection contains one 510(k) record, K261677, with a Substantially Equivalent decision; this is a count of filings in the collection as of November 20, 2026, not a measure of total portfolio, sales or safety performance. No recall records appear in the collection. The sources do not document customers, certifications, commercial availability, pricing or independent testing of AIRA. [1]